Sign in
CompletedNo phase

Apneic Oxygenation by Transnasal Humidified Rapid Insufflation Ventilator Exchange Obstructive Sleep Apnea Patients

Key facts

Who runs it
Beijing Tongren Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
56 people enrolled
Started
1 Sept 2024
Ended
13 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • THRIVE
  • THRIVE combine nasopharyngeal airway
Record updated
17 April 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • patients aged between 18 and 75 years requiring general anesthesia
  • American society of Anesthesiologists (ASA) physical status classification system: I - III
  • diagnosed as OSA

Who cannot take part

  • patients with previous or anticipated difficult facemask ventilation or intubation,
  • Patients with chronic respiratory disease, uncontrolled hypertension, ischemic heart disease, congestive heart failure, increased intracranial pressure, gastroesophageal reflux disease,
  • patients with known allergy or contraindication to propofol, remifentanil, rocuronium, or midazolam
  • patients' arterial hemoglobin saturation < 98% after preoxygenation,
  • patients were nasal obstruction
  • patients who were unable to give informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to compare effectiveness of different methods of achieving oxygenation in obstructive sleep apnea patients. The investigators intend to compare transnasal humidified rapid-insufflation ventilator exchange (THRIVE) combined with nasopharyngeal airway with THRIVE alone.

The 2 groups in the trial

  • oxygenation using THRIVE techniqueExisting treatment, for comparison

    oxygenation delivered via nasal high flow humidified oxygen (Optiflow) . 70 litres/minute

    Treatment: THRIVE

  • THRIVE combined nasopharyngeal airwayTreatment being tested

    oxygenation delivered via nasopharyngeal airway and THRIVE technique. 70 litres/minute

    Treatment: THRIVE combine nasopharyngeal airway

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Apnoeic Oxygenation in Obstructive Sleep Apnea: a Randomised Controlled Trial Comparing Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) Combined With Nasopharyngeal Airway and THRIVE Alone
Publications
Record updated
17 April 2025
Apneic Oxygenation by Transnasal Humidified Rapid Insufflation Ventilator Exchange Obstructive Sleep Apnea Patients (NCT06581588) – Frontlight Research